Article

A European survey of diagnostic methods and testing protocols for Clostridium difficile

Clinical Microbiology and Infection (Impact Factor: 4.58). 10/2003; 9(10):989 - 996. DOI: 10.1046/j.1469-0691.2003.00683.x
Source: PubMed

ABSTRACT Objective To conduct a survey of the methods used in clinical microbiology laboratories in Europe to diagnose infection with Clostridium difficile.Methods A questionnaire was devised and sent to a co-ordinating member of the Study Group in each of eight European countries. This co-ordinator was in charge of forwarding the questionnaire to hospital laboratories arbitrarily selected. The number of laboratories in each country was determined on the basis of one laboratory for 10 000 beds of hospitalization. This questionnaire covered different aspects pertaining to Clostridium difficile associated to diarrhea (CDAD) diagnosis such as circumstances of request, criteria used for undertaking C. difficile investigations, methods used for the diagnosis, etc.Results A total of 212 questionnaires were completed and submitted for analysis: 87.7% of laboratories reported routinely performing C. difficile diagnostic tests. Methods used included toxin detection (93%), culture (55%), and glutamate dehydrogenase (GDH) detection (5.9%). Among the laboratories detecting toxins, different enzyme immunoassays (EIA) and cytotoxicity assays were used in 79% and 17.3% of cases, respectively. Among the different strategies reported, 4.8% were considered suboptimal for the diagnosis of C. difficile infections, but marked discrepancies could be observed between countries. The overall incidence (median) of CDAD was estimated at 1.1 for 1000 patient admissions.Conclusion The results of this study suggest marked discrepancies between laboratories and also between countries regarding the criteria by which C. difficile is investigated for, and the methods and the strategies that are used for the diagnosis of C. difficile. These discrepancies could be explained by the lack of clear guidelines for C. difficile diagnosis in each country, and by the importance that physicians attach to C. difficile. Precise guidelines for C. difficile diagnosis would be the first step to make possible accurate comparison of the incidence and the epidemiology of CDAD from one hospital to another or from one country to another.

2 Bookmarks
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence and mortality rate of Clostridium difficile infection have increased remarkably in both hospital and community settings during the last two decades. The growth of infection may be caused by multiple factors including inappropriate antibiotic usage, poor standards of environmental cleanliness, changes in infection control practices, large outbreaks of C. difficile infection in hospitals, alteration of circulating strains of C. difficile, and spread of hypervirulent strains. Detection of high-risk populations could be helpful for prompt diagnosis and consequent treatment of patients suffering from C. difficile infection. Metronidazole and oral vancomycin are recommended antibiotics for the treatment of initial infection. Current treatments for C. difficile infection consist of supportive care, discontinuing the unnecessary antibiotic, and specific antimicrobial therapy. Moreover, novel approaches include fidaxomicin therapy, monoclonal antibodies, and fecal microbiota transplantation mediated therapy. Fecal microbiota transplantation has shown relevant efficacy to overcome C. difficile infection and reduce its recurrence.
    Scientifica. 01/2014; 2014:916826.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Prospective, hospital-based surveillance for Clostridium difficile-associated disease (CDAD) was conducted in Barcelona (Spain) to describe the epidemiology of this condition and investigate the risk factors for an unfavorable outcome.Methods: All patients diagnosed with CDAD during 2009 were included. Using logistic regression modeling, we analyzed potential risk factors associated with recurrent and complicated CDAD, defined as a colectomy requirement or death within 30 days.Results: There were 365 episodes of CDAD, yielding an incidence of 22.5 cases/105 person-years, 1.22 cases/103 hospital-discharges, and 1.93 cases/104 patient-days. The main ribotypes identified were 241 (26%), 126 (18%), 078 (7%), and 020 (5%). PCR ribotype 027 was not detected. Among 348 cases analyzed, 232 (67%) patients cured, 63 (18%) recurred, and 53 (15%) had complicated CDAD. Predictors of complicated CDAD were continued use antibiotics following CDAD diagnosis (odds ratio [OR], 2.009; 95% confidence interval [CI], 1.012-3.988; P=0.046), Charlson comorbidity index score (OR, 1.265; 95% CI, 1.105-1.449; P=0.001), and age (OR, 1.028; 95% CI, 1.005-1.053; p=0.019). Leukocyte count >15×103 cells/mL (OR 2.277; 95% CI 1.189-4.362; P=0.013), continuation of proton pump inhibitors (PPIs) after CDAD diagnosis (OR 2.168; 95% CI 1.081-4.347; P=0.029), and age (OR 1.021; 95% CI 1.001-1.041; P=0.036) were independently associated with higher odds of recurrence.Conclusions: The incidence of CDAD in Barcelona during 2009 was located at the lower end of the previously described range in Europe. Our analysis suggests that continuation of non-C. difficile antibiotics and PPIs in patients diagnosed with CDAD is associated with unfavorable clinical outcomes.
    Journal of clinical microbiology 02/2013; · 4.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clostridium difficile (CD) can cause a significant and transmissible disease in animals and humans, with poorly understood epidemiology. Animals have been suggested as a possible source of infection and environment contamination. It is necessary that a precise and rapid diagnostic tool is available for the detection of CD from clinical and/or environmental samples. A quantitative real-time PCR (qPCR) protocol for CD detection defined by Penders et al. (2005) was modified. The modified protocol, supported by a novel extraction method, was tested on CD spiked cattle feces and clinical fecal samples from calves. Quantification was done targeting CD 16S rRNA gene. Three different commonly used TaqMan universal PCR master mixes were also compared. Results indicate that the modified protocol is very sensitive with a LOD of 7.72 CD cells/g CD spiked feces. The protocol is capable of precise quantification with LOQ of 77.2 CD cells/g CD-spiked feces, R(2) between 0.9957 and 0.9968, isolation efficiency from 87.89% to 90.96% and an inter-assay CV ranging from 3.71% to 9.57%. The qPCR protocol for the detection and quantification of CD from animal feces investigated and described in this paper using MIQE guidelines has the lowest detection and quantification limit published to date. Therefore, it can be implemented for precise epidemiological investigations of CD infections in animals and humans. © 2013 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.
    FEMS Microbiology Letters 02/2013; · 2.05 Impact Factor

Full-text (4 Sources)

View
13 Downloads
Available from
Jul 3, 2014